Development and Validation of [(3)H]OF-NB1 for Preclinical Assessment of GluN1/2B Candidate Drugs

GluN2B-enriched N-methyl-D-aspartate receptors (NMDARs) are implicated in several neurodegenerative and psychiatric diseases, such as Alzheimer’s disease. No clinically valid GluN1/2B therapeutic exists due to a lack of selective GluN2B imaging tools, and the state-of-the-art [(3)H]ifenprodil shows...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahmed, Hazem, Gisler, Livio, Elghazawy, Nehal H., Keller, Claudia, Sippl, Wolfgang, Liang, Steven H., Haider, Ahmed, Ametamey, Simon M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9416150/
https://www.ncbi.nlm.nih.gov/pubmed/36015108
http://dx.doi.org/10.3390/ph15080960

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9416150/
https://www.ncbi.nlm.nih.gov/pubmed/36015108
http://dx.doi.org/10.3390/ph15080960

Ejemplares similares